Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma

ESMO Open. 2020 Jun;5(3):e000756. doi: 10.1136/esmoopen-2020-000756.

Authors

Lauriane Eberst¹, Philippe A Cassier², Mehdi Brahmi², Franck Tirode², Jean-Yves Blay³

Affiliations

¹ Department of Medical Oncology, Centre Leon Berard, Lyon, France. Electronic address: [email protected].
² Department of Medical Oncology, Centre Leon Berard, Lyon, France.
³ Department of Medical Oncology, Centre Leon Berard, Lyon, France; Université Claude Bernard Lyon 1, Villeurbanne, France.

No abstract available

Keywords: angiomatoid fibrous histiocytoma; interleukin 6; paraneoplastic tumour inflammation; sarcoma; tocilizumab.

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Histiocytoma, Malignant Fibrous* / drug therapy
Humans
Male
Middle Aged
Positron Emission Tomography Computed Tomography
Tomography, X-Ray Computed

Substances

Antibodies, Monoclonal, Humanized
tocilizumab